Nasal spray compositions exhibiting increased retention in the nasal cavity
US5897858A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 4, 1997 |
| Grant date | Apr 27, 1999 |
| Priority date | — |
| Expiry date | Nov 4, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4402
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aqueous nasal spray compositions containing: PA1 0.001-2% by weight/volume of a medicament selected from the group consisting of chlorpheniramine maleate, oxymetazoline hydrochloride and mixtures thereof; PA1 0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone having an average molecular weight of about 10,000 to 360,000 and mixtures thereof; PA1 2.5 to 10.00% by weight/volume of polyethylene glycol; PA1 1.00 to 10.00% by weight/volume of a moisturizing agent other than polyethylene glycol; PA1 0.01 to 0.05% by weight/volume of disodium edetate; PA1 0.001 to 0.3% by weight/volume of an antimicrobial preservative; PA1 0.20 to 5.00% by weight/volume of an aromatic alcohol; PA1 a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0; and PA1 QS water.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.